Clinical Trial

A new T-cell therapy, RPTR-1-201, enters clinical trials, offering hope for hard-to-treat solid tumors by targeting a shared, multi-cancer marker.

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

A breakthrough review validates harnessing neutrophils, the immune system's foot soldiers, for cancer, with a new therapy now heading to human trials.

A new imaging tool eliminates background noise, offering a revolutionary, high-definition view into the cellular processes that drive life and disease.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

New preclinical data for InnoCare's ICP-B794 reveals a wider safety window and power to overcome drug resistance, positioning it as a top contender.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Following a breakthrough in chondrosarcoma, Inhibrx Biosciences is set to reveal pivotal data for its drug ozekibart in the vast colorectal cancer market.

Atsena Therapeutics gets the green light for the final trial phase of a promising gene therapy, offering the first real hope for patients with X-linked retinoschisis.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

A new class of ultra-flexible graphene brain implants has safely decoded neural signals in a first-in-human study, heralding a new era for surgery.

With Cigna's backing, Accord's IMULDOSA is set to challenge a blockbuster drug, promising significant savings for patients and the healthcare system.

A Shanghai-based firm's new approach could create cancer-fighting cells inside the body, slashing costs and wait times for CAR-T therapy.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

A landmark real-world study from England shows maternal RSV vaccination slashes infant hospitalizations, validating a powerful new shield for newborns.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

Presented at AACR 2026, first-in-class antibody IMT-009 shows clinical benefit in tough cancers, potentially paving the way for a new precision therapy.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

New clinical consensus on ammonia and scrutiny of a standard antibiotic are creating a perfect storm for Yaqrit's promising new liver disease treatments.